Scancell soars following cancer vaccine clinical results

Shares in Scancell, a developer of therapeutic cancer vaccines, surged on Thursday morning following publication of the group's results from its clinical vaccine trials.

Shares in Scancell, a developer of therapeutic cancer vaccines, surged on Thursday morning following publication of the group's results from its clinical vaccine trials.

The stock jumped 13.4% to 55p by 10:07, pulling back after an earlier high of 58p.

The results provide the first evidence that Scancell's ImmunoBody vaccine approach is producing an immune response in cancer patients which may also be associated with clinical benefits.

Preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma were encouraging. Of the six patients allocated to the 2mg and 4mg dose cohorts and who received at least four doses of SCIB1, four showed a vaccine-induced T cell response to treatment.

Although the study was not designed primarily to measure tumour response, one patient in the 4mg dose cohort with multiple tumour lesions at study entry had a differential response to treatment including partial or complete regression of all lung metastases.

A further two patients who had all their tumours surgically removed prior to SCIB1 treatment have remained disease-free more than a year after first dosing. The vaccine produced very few side effects, none of which were serious.

Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell Holdings, commented: "This is a defining moment for Scancell. These preliminary yet encouraging results provide the first clinical endorsement for the groundbreaking cancer vaccine research undertaken by Scancell under the scientific leadership of Professor Durrant.

"We will continue to gather additional longer term data on these patients and those in Part 2 of the study during 2013."

MF

Recommended

Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares in the week ending 5 August, providing an insight into how investors are thinking and where opportunities may l…
9 Aug 2022
Where to find inflation-resistant stocks
Investment strategy

Where to find inflation-resistant stocks

Terry Smith’s latest update contains some valuable pointers for investors looking to protect against inflation.
8 Aug 2022
A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022